Key facts
- It has raised $10.6M; the latest was Grant ($61.0M) in Oct 2024.
- Notable investors include Insight Partners (New York), Johnson & Johnson Innovation - JLABS, ARPA-H, Angel, KdT Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cirsium Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Cirsium Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cirsium Biosciences
Operator of a research and development biotechnology company intended for the production of gene therapies. The company uses whole plants as the production platform for developing viral vector manufacturing technologies, enabling clients to address current issues with cost, capacity, scalability, and speed for the production of gene therapies.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 22
- Website
- cirsiumbio.com/
- Ownership
- Privately Held (backing)
Cirsium Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cirsium Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cirsium Biosciences in its N-PORT filings yet. We sweep new filings monthly.